Guidelines for the management of chronic hepatitis C in patients infected after substance use

Antidotes/therapeutic use; Antiviral Agents/therapeutic use; Behavior Therapy; Belgium/epidemiology; Combined Modality Therapy; Comorbidity; Evidence-Based Medicine; Female; Follow-Up Studies; Hepatitis C, Chronic/diagnosis/epidemiology/therapy; Humans; Male; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Substance-Related Disorders/diagnosis/epidemiology/therapy; Treatment Outcome

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Robaeys, G.

Buntinx, F.

Bottieau, E.

Bourgeois, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > HOSPITALISATION - CARDIOLOGIE (SN -2)

Brenard, R.

Colle, I.

De Bie, J.

Mathei, C.

Mulkay, J. P.

Van Damme, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > HOSPITALISATION - S.I. CHIRURGICAUX (SI +1D)

More authors (13 more)

Language :

English

Title :

Guidelines for the management of chronic hepatitis C in patients infected after substance use

Publication date :

2005

Journal title :

Acta Gastro-Enterologica Belgica

ISSN :

0001-5644

eISSN :

1784-3227

Publisher :

Acta Medica Belgica, Bruxelles, Belgium

Volume :

Issue :

Pages :

38-45

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 September 2010

Statistics

Number of views

37 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B., Diagnosis management, and treatment of hepatitis C (2004) Hepatology, 39, pp. 1147-1171
Nelson, M.R., Matthews, G., Brook, M.G., Main, J., BHIVA guidelines: Coinfection with HIV and chronic hepatitis C virus (2003) HIV Med., 4 (SUPPL. 1), pp. 52-62
Alter, M.J., Kruszon-Moran, D., Nainan, O.V., Mc Quillan, G.M., Gao, F., Moyer, L.A., Kaslow, R.A., Margolis, H.S., The prevalence of hepatitis C virus infection in the United States, 1988 through, 1994 (1999) N. Engl. J. Med., 341, pp. 556-562
Alter, M.J., Prevention of spread of hepatitis C (2002) Hepatology, 36, pp. S93-S98
Mathei, C., Buntinx, F., Van Damme, P., Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: A systematic review (2002) J. Viral Hepat., 9, pp. 157-173
Mathei, C., Robaeys, G., Van Ranst, M., Van Damme, P., Buntinx, F., The epidemiology of hepatitis C among drug users in Belgium (2005) Acta Gastroenterol. Belg., , in press
Jose, M., Curtu, S., Gajardo, R., Jorquera, J.I., The effect of storage at different temperatures on the stability of Hepatitis C virus RNA in plasma samples (2003) Biologicals, 31, pp. 1-8
De Moreau De Gerbeheaye, A.I., Bodeus, M., Robert, A., Horsmans, Y., Goubau, P., Stable hepatitis C virus RNA detection by RT-PCR during four days storage (2002) BMC Infect. Dis., 2, p. 22
Fontana, R.J., Lok, A.S., Noninvasive monitoring of patients with chronic hepatitis C (2002) Hepatology, 36 (SUPPL. 1), pp. S57-S64
Foster, G.R., Goldin, R.D., (2002) Management of Chronic Viral Hepatitis, , Taylor and Francis Group, 11 New Fetter Lane, London EC4P 4EE
Pawlotsky, J.M., Use interpretation of virological tests for hepatitis C (2002) Hepatology, 36 (SUPPL. 1), pp. S65-S73
Pontisso, P., Bellati, G., Brunetto, M., Chemello, L., Colloredo, G., Di Stefano, R., Nicoletti, M., Colucci, G., Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity? (1999) Hepatology, 29, pp. 585-589
Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Okuda, K., The long-term pathological evolution of chronic hepatitis C (1996) Hepatology, 23, pp. 1334-1340
Fontaine, H., Nalpas, B., Poulet, B., Carnot, F., Zylberberg, H., Brechot, C., Pol, S., Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C (2001) Hum. Pathol., 32, pp. 904-909
Marcellin, P., Asselah, T., Boyer, N., Fibrosis disease progressionin hepatitis C (2002) Hepatology, 36 (SUPPL. 1), pp. S47-S56
Michielsen, P., Bottieau, E., Treatment of chronic hepatitis C in the setting of HIV co-infection (2005) Acta Gastroenterologica Belgica, , in press
Gebo, K.A., Herlong, H.F., Torbenson, M.S., Jenckes, M.W., Chander, G., Ghanem, K.G., El-Kamary, S.S., Bass, E.B., Role of liver biopsy in management of chronic hepatitis C: A systematic review (2002) Hepatology, 36 (SUPPL. 1), pp. S161-S172
Gebo, K.A., Chander, G., Jenckes, M.W., Ghanem, K.G., Herlong, H.F., Torbenson, M.S., El-Kamary, S.S., Bass, E.B., Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review (2002) Hepatology, 36 (SUPPL. 1), pp. S 84-S 92
De Franchis, R., Updating Consensus in Portal Hypertension Report of the Baveno III. Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension (2000) J. Hepatol., 33, pp. 846-852
Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., Christensen, E., Rodes, J., Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference (2001) J. Hepatol., 35, pp. 421-430
Thomas, D.L., Hepatitis C and human immunodeficiency virus infection (2002) Hepatology, 36 (SUPPL. 1), pp. S201-S209
Kane, A., Lloyd, J., Zaffran, M., Simonsen, L., Kane, M., Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: Model-based regional estimates (1999) Bull. World Health Organ., 77, pp. 801-807
Van Vlierberghe, H., Borbath, I., Delwaide, J., Henrion, J., Michielsen, P., Verslype, C., BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma (2004) Acta Gastroenterol. Belg., 67, pp. 14-25
Sylvestre, D., Treating hepatitis C in methadone maintenance patients: An interim analysis (2002) Drug Alcohol Depend., 67, pp. 103-107
Backmund, M., Meyer, K., Von Zielonk, A.M., Eichenlaub, D., Treatment of hepatitis C infection in injection drug users (2001) Hepatology, 34, pp. 188-193
Van Thiel, D.H., Anantharaju, A., Creech, S., Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse (2003) Am. J. Gastroentol., 98, pp. 2281-2288
Jowett, S.L., Agarwal, K., Smith, B.C., Craig, W., Hewett, M., Bassendine, D.R., Gilvarry, E., Bassendine, M.F., Managing chronic hepatitis C acquired through intravenous drug use (2001) QJM, 94, pp. 153-158
Bourliere, M., Halfon, P., Portal, I., Treatment of chronic hepatitis C in special groups (2002) Gastroenterol. Clin. Biol., 26, pp. B 238-B 247
Robaeys, G., Van Vlierberghe, H., Mathei, C., Van Ranst, M., Bruckers, L., Buntinx, F., Compliance effect of treatment for chronic hepatitis C in intravenous drug users (2003) J. Hepatol., 38 (SUPPL. 2), p. 165
Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., Heldwein, W., Loeschke, K., Adherence mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups (2003) Hepatology, 37, pp. 443-451
Mauss, S., Berger, F., Goelz, J., Jacob, B., Schmutz, G., A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance (2004) Hepatology, 40, pp. 120-124
Cournot, M., Glibert, A., Castel, F., Druart, F., Imani, K., Lauwers-Cances, V., Morin, T., Management of hepatitis C in active drugs users: Experience of an addiction care hepatology unit (2004) Gastroenterol. Clin. Biol., 28, pp. 533-539
Schaefer, M., Heinz, A., Backmund, M., Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? (2004) Addiction, 99, pp. 1167-1175
Kresina, T.F., Seeff, L.B., Francis, H., Hepatitis C infection and injection drug use: The role of hepatologist in evolving treatment efforts (2004) Hepatology, 40, pp. 516-519
Robaeys, G., Buntinx, F., Treatment of hepatitis C viral infections in substance abusers in, 2005 (2005) Acta Gastroenterol. Belg., , in press
Edlin, B.R., Seal, K.H., Lorvick, J., Kral, A.H., Ciccarone, D.H., Moore, L.D., Lo, B., Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users? (2001) N. Engl. J. Med., 345, pp. 211-214
Edlin, B.R., Prevention treatment of hepatitis C in injection drug users (2002) Hepatology, 36, pp. S210-S219
Verrando, R., Robaeys, G., Mathei, C., Buntinx, F., Methadone buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use (2005) Acta Gastroenterol. Belg., , in press
De Bie, J., Robaeys, G., Buntinx, F., Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice (2005) Acta Gastroenterol. Belg., , in press
Wong, J.B., Koff, R.S., Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effective analysis (2000) Ann. Intern. Med., 133, pp. 665-675
Chander, G., Sulkowski, M.S., Jenckes, M.W., Torbenson, M.S., Herlong, H.F., Bass, E.B., Gebo, K.A., Treatment of chronic hepatitis C: A systematic review (2002) Hepatology, 36 (SUPPL. 1), pp. S135-S144
Michielsen, P., Brenard, R., Bourgeois, N., De Galocsy, C.H., Delwaide, J., Henrion, J., Horsmans, Y., Van Vlierberghe, H., Hepatitis C: Screening, treatment and prevention practical guidelines (2003) Acta Gastroenterol. Belg., 66, pp. 15-19
Gerlach, J.T., Diepolder, H.M., Zachoval, R., Gruener, N.H., Jung, M.C., Ulsenheimer, A., Schraut, W.W., Pape, G.R., Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance (2003) Gastroenterology, 125, pp. 80-88
Delwaide, J., Bourgeois, N., Gerard, C., De Maeght, S., Mokaddem, F., Wain, E., Bastens, B., Van Vlierberghe, H., Treatment of acute hepatitis C with interferon alpha-2b: Early initiation of treatment is the most effective predictive factor of sustained viral response (2004) Aliment. Pharmacol. Ther., 20, pp. 15-22
Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Manns, M.P., Treatment of acute hepatitis C with interferon alfa-2b (2001) N. Engl. J. Med, pp. 1452-1456
Davis, G.L., Wong, J.B., Mc Hutchison, J.G., Manns, M.P., Harvey, J., Albrecht, J., Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C (2003) Hepatology, 38, pp. 645-652
Di Martini, A., Weinrieb, R., Hepatitis C in methadone maintenance patients: Prevalence and public policy implications (2003) Am. J. Transplant., 3, pp. 1183-1184
Kanchana, T.P., Kaul, V., Manzarbeitia, C., Reich, D.J., Hails, K.C., Munoz, S.J., Rothstein, K.D., Liver transplantation for patients on methadone maintenance (2002) Liver Transpl., 8, pp. 778-782
Weinrieb, R.M., Barnett, R., Lynch, K.G., De Piano, M., Atanda, A., Olthoff, K.M., A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients (2004) Liver Transpl., 10, pp. 97-106
Di Martini, A., Weinrieb, R., Fireman, M., Liver transplantation in patients with alcohol and other substance use disorders (2002) Psych. Clin. N. Amer., 25, pp. 195-208
Koch, M., Banys, P., Liver transplantation and opioid dependence (2001) JAMA, 28, pp. 1056-1058
Dieperink, E., Ho, S.B., Thuras, P., Willenbring, M.L., A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C (2003) Psychosomatics, 44, pp. 104-112
Wichers, M.C., Koek, G.H., Robaeys, G., Praamstra, A.J., Maes, M., Early Increase in Vegetative Symptoms Predicts IFN-Alpha-Induced Depression, , Accepted: Psychological Medicine
Wichers, M.C., Koek, G.H., Robaeys, G., Praamstra, A.J., Maes, M., Involvement of Indoleamine 2,3-Dioxygenase (IDO) in IFN-Alpha-Induced Depressive Symptoms Through Its Modulation of the Kynurenine Pathway, , Accepted: Molecular Psychiatry
Hauser, P., Soler, R., Reed, S., Kane, R., Gulati, M., Khosla, J., Kling, M.A., Meyers, C.A., Prophylactic treatment of depression induced by interferon-alpha (2000) Psychosomatics, 41, pp. 439-441
Mehta, S.H., Cox, A., Hoover, D.R., Wang, X.H., Mao, Q., Ray, S., Strathdee, S.A., Thomas, D.L., Protection against persistence of hepatitis C (2002) Lancet, 359, pp. 1478-1483
Dalgard, K., Bjoro, K., Hellum, K., Myrvang, B., Skaug, K., Gutigard, B., Bell, H., Treatment of chronic hepatitis C in injecting drug users: 5 Years' follow-up (2002) European Addiction Research, 8, pp. 45-49
Quaglio, G., Talamani, G., Lugoboni, F., Lechi, A., Venturini, L., Jarlais, D.C., Mezzelani, P., Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response (2002) Addiction, 97, pp. 985-992
Lum, P.J., Ochoa, K.C., Hahn, J.A., Shafer, K.P., Evans, J.L., Moss, A.R., Hepatitis B virus immunization among young injection drug users in San Francisco, CA: The UFO study (2003) Am. J. Public Health, 93, pp. 919-923
Lamagni, T.L., Hope, V.D., Davison, K.L., Parry, J.V., Gill, O.N., Failure to vaccinate current injecting drug users against hepatitis B in England and Wales (2001) Commun Dis. Public Health, 4, pp. 71-72
Mc Gregor, J., Marks, P.J., Hayward, A., Bell, Y., Slack, R.C., Factors influencing hepatitis B vaccine uptake in injecting drug users (2003) J. Public Health Med., 25, pp. 165-170
Soriano, V., Miro, J.M., Garcia-Samaniego, J., Torre-Cisneros, J., Nunez, M., Del Romero, J., Martin-Carbonero, L., Lissen, E., Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations (2004) J. Viral Hepat., 11, pp. 2-17
Soriano, V., Perez-Olmeda, M., Rios, P., Nunez, M., Garcia-Samaniego, J., Lahoz-Gonzalez, J., Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients (2004) AIDS Res. Hum. Retrov., 20, pp. 351-353
Mauss, S., Valenti, W.A., Depamphilis, J.B., Duff, F.B., Cupelli, L.B., Passe, S.B., Solsky, J.B., Larrey, D.E., Risk factors for hepatic decompensation in patients with HIV/HCV co infection and liver cirrhosis during interferon-based therapy (2004) AIDS, 18, pp. 21-25
Pol, S., Traitement de l'hépatite chronique C chez les malades ayant une co-infection VIH: Efficacité et tolérance (2002) Gastroenterol. Clin. Biol., 26, pp. B264-B273
Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Perronne, C., Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial (2004) JAMA, 292, pp. 2839-2848
Torriani, F.J., Rodiguez-Torres, M., Rockstroh, J.K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Dieterich, D.T., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients (2004) N. Engl. J. Med., 351, pp. 438-450